- Service Name
VLN® Reduced Nicotine Content Cigarettes
- Industry
Biotechnology, Health, Tobacco Harm Reduction, Plant Science
- Main Value Proposition
The primary value offered is the ability to help smokers reduce their nicotine intake and overall cigarette consumption, thereby improving public health.
- Description
22nd Century Group, Inc. is a biotechnology company that focuses on improving human health through plant science, specifically by developing reduced nicotine content tobacco products. Their flagship product, VLN®, contains 95% less nicotine than conventional cigarettes, aiming to assist smokers in reducing their intake.
- Key Features
95% less nicotine than conventional cigarettes; FDA MRTP authorization for reduced nicotine content cigarettes; Innovative plant breeding technologies including genetic engineering and gene-editing; Focus on harm reduction and smoking cessation
- Use Cases
The service is most valuable for smokers looking to reduce their nicotine intake, public health organizations aiming to decrease smoking-related harm, and researchers in the field of tobacco harm reduction.
- Competitive advantages
First and only FDA-authorized reduced nicotine content cigarette; Proprietary plant biotechnology that enhances health benefits; Strong focus on harm reduction and public health improvement
- Strengths
The company has a strong commitment to innovation in plant biotechnology, a unique product offering that addresses public health concerns, and a proven track record of regulatory approval.
- Positioning
22nd Century Group positions itself as a leader in tobacco harm reduction through innovative biotechnology, aiming to transform the smoking experience into a healthier alternative.
- Audience
The target users include smokers seeking to quit or reduce their smoking habits, public health advocates, and regulatory bodies focused on tobacco control.
- CTA
Learn More
- Tags
Tobacco Harm Reduction
Biotechnology
Public Health
Smoking Cessation
- Tagline
Empowering plants for a healthier future
- Tone of Voice
Innovative, authoritative, health-focused
- Differentiation
22nd Century Group is unique in the market due to its patented technology that allows for the control of nicotine biosynthesis in tobacco plants, making it the only company with FDA-authorized reduced nicotine content cigarettes.
- Brand Positioning
The brand identity emphasizes health improvement through scientific innovation, focusing on the reduction of smoking-related harm.
- Founded
1998-01-01
- Founders
Joseph Pandolfino